Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1989 Jun;80(6):562–569. doi: 10.1111/j.1349-7006.1989.tb01676.x

Enhancement of Therapeutic Effect of Interleukin‐2 on Spontaneous Pulmonary Metastases of Lewis Lung Carcinoma by Killer Helper Factor Associated with Increased Induction of Killer Activity

Katsuyuki Fukuta 1, Saburo Sone 1, Misa Kitahara 2, Masaji Okada 2, Takeshi Ogura 1
PMCID: PMC5917794  PMID: 2503476

Abstract

Killer helper factor (KHF) was previously found to be produced by a human T cell hybridoma, 24A CA2. We studied the therapeutic effects of interleukin‐2 (IL‐2) and KHF on the inhibition of pulmonary mctastascs of syngeneic Lewis lung carcinoma (3LL) in C57BL/6N mice. Multiple subcutaneous (sc) injections of IL‐2 plus KHF had significantly more effect than injections of IL‐2 alone in inhibiting spontaneous pulmonary mctastascs and prolonging survival of the mice. The effect of KHF with IL‐2 on induction of lymphokine(IL‐2)‐activated killer (LAK) activity against P‐29 cells was examined in the murine system. Spleen cells generated LAK activity after incubation for 4 days with more than 500 U/ml of IL‐2. In contrast, KHF alone did not render spleen cells cytotoxic. The combination of these lymphokines at subthreshold concentrations, however, resulted in significant in vitro induction of LAK activity. The LAK activity of splenocytes incubated with IL‐2 plus KHF was maximal after 4 days, and persisted for longer than that of cells treated with IL‐2 alone. The LAK cells induced by KHF plus IL‐2 were also cytotoxic to FBL and YAC‐1 cells. Moreover, spleen cells of mice bearing lung metastases could be induced to the cytotoxic state by sc injections of IL‐2 plus KHF. These results indicate that combination treatment with IL‐2 and the new lymphokine KHF should he useful clinically in inducing LAK activity for inhibition of pulmonary metastases.

Keywords: Lung metastasis, Interleukin‐2, Killer helper factor, LAK induction

Full Text

The Full Text of this article is available as a PDF (457.4 KB).

REFERENCES

  • 1. ) Mule , J. J. , Shu , S. , Schwarz , S. L. and Rosenberg , S. A.Successful adoptive immunotherapy of established pulmonary metastases of multiple sarcomas with lymphoktne‐activated killer cells and recombinant interleukin‐ 2 . Science , 225 , 1487 – 1489 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Rosenberg , S. A. , Mule , J. J. , Spiess , P. J. , Reichert , C. M. and Schwarz , S. L.Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high‐dose recombinant inter‐leukin‐2 . J. Exp, Med. , 161 , 1169 – 1188 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. ) Lafreniere , R. and Rosenberg , S. A.Successful immunotherapy of murine experimental hepatic metastases with lymphokine‐activated killer cells and recombinant interleukin 2 . Cancer Res. , 45 , 3735 – 3741 ( 1985. ). [PubMed] [Google Scholar]
  • 4. ) Rosenberg , S. A. , Lotze , M. T. , Muul , L. M. , Leitman , S. , Change , A. E. , Ettinghausen , S. E. , Matory , Y. L. , Skibber , J. M. , Shiloni , E. , Vetto , J. T. , Seipp , C. A. , Simpson , C. and Reichert , C. M.Observation on the systemic administration of autologous lymphokine‐activated killer cells and recombinant interleukin‐2 to patients with metastatic cancer . N. Eng. J, Med. , 313 , 1485 – 1492 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) West , W. H. , Tauer , K. W , Yanelli , J. R. , Marshall , G. D. , Orr , D. W. , Thurmann , G. B. and Oldham , R. K.Constant‐infusion recombinant interleukin‐2 in adoptive immunotherapy of advanced cancer . N. Eng, J. Med. , 316 , 898 – 905 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Rosenberg , S.A. Immunotherapy of cancer using interleukin 2: current status and future prospect . Immunol. Today , 9 , 58 – 62 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Mule , J. J. , Shu , S. , Shuwartz , S. L. and Rosenberg , S. A.The antitumor efficacy of lymphokine‐activated killer cells and recombinant interleukin‐2 in vivo . J. Immunol. , 135 , 646 – 652 ( 1985. ). [PubMed] [Google Scholar]
  • 8. ) Grimm , E. A. , Mazutnder , A. , Zhang , H. Z. and Rosenberg , S. A.Lymphokme‐activated killer cell phenomenon . J. Exp. Med. , 155 , 1823 – 1841 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Henny , C. S. , Kuribayashi , K. , Kern , D. E. and Gills , S.Interleukin‐2 augments natural killer cell activity . Nature , 291 , 335 – 338 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Sone , S. , Inamura , N. , Nii , A. and Ogura , T.Heterogeneity of human Iymphokine(IL‐2) ‐activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes . Int. J. Cancer , in press . [DOI] [PubMed]
  • 11. ) Ettinghauzen , S. E. and Rosenberg , S. A.Immunotherapy of marine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin‐2 . Cancer Res. , 46 , 2784 – 2792 ( 1986. ). [PubMed] [Google Scholar]
  • 12. ) Donohue , J. H. and Rosenberg , S. A.The fate of interleukin‐2 after in vivo administration . J. Immunol. , 130 , 2203 – 2208 ( 1983. ). [PubMed] [Google Scholar]
  • 13. ) Rosenberg , S. A. , Lotze , M. T. , Muul , L. M. , Chang , A. E. , Avis , F. P. , Leitman , S. , Linehan , W. M. , Robertson , C. N. , Lee , R. E. , Rubin , J. T. , Seipp , C. A. , Simpson , C. G , and White , D. S.A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high dose interleukin‐2 alone . N. Eng. J. Med. , 316 , 889 – 897 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Brunda , M. J. , Bellantoni , D. and Sulich , V.In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells . Int. J. Cancer , 40 , 365 – 371 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Winkelhake , J. L. , Stampfl , S. and Zimmerman , R. J.Synergistic effect of combination therapy with human recombinant interleukin‐2 and tumor necrosis factor in murine tumor models . Cancer Res. , 47 , 3948 – 3953 ( 1987. ). [PubMed] [Google Scholar]
  • 16. ) McIntosh , J. K. , Mule , J. J. , Merino , M. J. and Rosenberg , S. A.Synergistic antitumor eifects of immunotherapy with recombinant interleukin‐2 and recombinant tumor necrosis factor‐a . Cancer Res. , 58 , 4011 – 017 ( 1988. ). [PubMed] [Google Scholar]
  • 17. ) Okada , M. , Yoshimura , N. , Ichimori , Y. , Kishimoto , S. , Nakai , S. , Nishino , N. and Kishimoto , T.Immunologic and molecular characterization of T cell‐derived T cell activating factor . J. Immunol. , 136 , 1288 – 1294 ( 1986. ). [PubMed] [Google Scholar]
  • 18. ) Kayne , J. , Gillis , S. , Mizel , S. B. , Shavach , E. M. , Malek , T. R. , Dinarello , C. A. , Lachman , L. B. and Janeway , C. A.Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin‐1 is required for the expression of receptors for interleukin‐2 . J. Immunol. , 133 , 1339 – 1345 ( 1984. ). [PubMed] [Google Scholar]
  • 19. ) Lubinski , J. , Fong , T. C. , Babbit , J. T. , Ransone , L. , Yodoi , J. and Bloom , E. T.Increased binding of IL‐2 and increased IL‐2 receptor mRNA synthesis are expressed by an NK‐like cell line in response to IL‐1 . J. Immunol. , 140 , 1903 – 1909 ( 1988. ). [PubMed] [Google Scholar]
  • 20. ) Kagawa , K. , Yamashita , T. , Tsubura , E. and Yamamura , Y.Inhibition of pulmonary metastases by Nocardia rubra cell wall skeleton, with special reference to macrophage activation . Cancer Res. , 44 , 665 – 670 ( 1984. ). [PubMed] [Google Scholar]
  • 21. ) Takenaga , K.Enhanced metastatic potential of cloned low‐metastatic Lewis lung carcinoma cells . Cancer Res. , 44 , 1122 – 1127 ( 1984. ). [PubMed] [Google Scholar]
  • 22. ) Yagi , M. , Yamashita , T. and Tsubura , E.Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma . Cancer Immunol, Immunother. , 19 , 198 – 204 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Sone , S. , Utsugi , T. , Nii , A. and Ogura , T.Differential effects of recombinant interferons α, β and γ on induction of human lymphokine (IL‐2)‐activated killer activity . J. Natl. Cancer Inst. , 80 , 425 – 431 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Gillis , S. and Mizel , S. B.T‐cell lymphoma model for the analysis of interleukin 1‐mediated T‐cell activation . Proc. Natl. Acad. Sci. USA , 78 , 1133 – 1137 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. ) Durum , S. K. , Schmidt , J. A. and Oppenheim , J. J.Interleukin 1: an immunological perspective . Annu. Rev. Immunol. , 3 , 263 – 287 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Wagner , H. , Hardt , C. , Rouse , B. T. , Rollinghoff , M. , Scheurich , P. and Pfizenmaier , K.Dissection of the proliferation and differentiative signals controlling murine cytotoxic T lymphocyte responses . J. Exp. Med. , 155 , 1876 – 1881 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. ) Werner , F. , Männel , D. N. , Katzer , B. , Kaltmann , B. , Krammer , P. H. , Diamantstein , T. and Dröge , W.Induction of IL 2 receptor expression and cytotoxicity of thymocytes by stimulation with TCF1 . J. Immunol. , 135 , 1160 – 1164 ( 1985. ). [PubMed] [Google Scholar]
  • 28. ) Kanagawa , O. and Chiller , J. M.Lymphokine‐mediated induction of cytolytic activity in a T cell hybridoma . J. Immunol. , 134 , 397 – 403 ( 1985. ). [PubMed] [Google Scholar]
  • 29. ) Raulet , D. H. and Bevan , M. J.A differentiation factor required for the expression of cytotoxic T‐cell function . Nature , 296 , 754 – 756 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Beardsley , T. R. , Pierschbacher , M. , Wetgel , G. D. and Hays , E. F.Induction of T‐cell maturation by a cloned line of thymic epithelium . Proc. Natl. Acad. Sci. USA , 80 , 6005 – 6009 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. ) Salahuddin , S. Z. , Markham , P. D. , Lindner , S. G. , Gootenberg , J. , Popovic , M. , Hemmi , H. , Sarin , P. S. and Gallo , R. C.Lymphokine production by cultured human T cells transformed by human T‐ceil leukemia‐lymphoma virus‐1 . Science , 225 , 1487 – 1489 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Yokota , S. , Shirasaka , T. , Nishikawa , H. , Hosoe , S. , Ikeda , T. , Komuta , K. , Kawae , L , Masuno , T. , Ogura , T. and Kishimoto , S.Augmentative effect of Nocardia rubra cell‐wall skeleton (N‐CWS) on lymphokine‐activated killer (LAK) cell induction . Cancer Immunoi Immunother. , 26 , 11 – 17 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. ) Damle , N. K. , Doyle , L. V. and Bradly , E. C.Interleukin 2‐activated human killer cells are derived from pheno‐typically heterogeneous precursors . J. Immunol. , 137 , 2814 – 2822 ( 1986. ). [PubMed] [Google Scholar]
  • 34. ) Grimm , E. A. , Ramsay , K. M. , Mazumder , A. , Wilson , D. J. , Djeu , J. Y. and Rosenberg , S. A.Lymphokine‐activated killer cell phenomenon II, Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus‐derived lymphocytes, and natural killer cells . J. Exp. Med. , 157 , 884 – 897 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. ) Ortaldo , J. R. , Mason , A. and Overton , R.Lymphokine‐ activated killer cells. Analysis of progenitors and effectors . J. Exp. Med. , 164 , 1193 – 1205 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. ) Okada , M. , Yoshimura , N. , Kaieda , T. , Yamamura , Y. and Kishimoto , T.Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules . Proc. Natl. Acad. Sei. USA , 78 , 7717 – 7721 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES